Blue Ocean Therapies: Untapped potential for pharmaceutical companies to launch new products

The prevailing mindset often revolves around launching products either successful in the West or those performing well locally.

Rarely do we encounter product launches diverging from these criteria.

This trend persists due to the perceived ease of attaining success with established therapies.

However, many organizations aspire to foster differentiation for success.
Achieving this becomes challenging when the vision and strategy are misaligned.

In today’s saturated pharmaceutical market, it becomes crucial to explore Blue Ocean Therapies, untapped approaches that diverge from conventional norms.

These therapies bridge therapy gaps in major diseases but remain outside the limelight. Despite their potential impact, organizations often hesitate due to the absence of market data.

Blue ocean therapies have documented mechanism of action and backed with clinical studies. Some may have less number of clinical studies but then it’s an opportunity of conducting Phase 4 clinical studies.

It is imperative for organizations to transcend conventional practices and undertake a thorough examination of the potential inherent in Blue Ocean Therapies. Such an exploration has the potential to make a substantial difference for both the organization and mankind.